These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28834692)

  • 1. Soluble Extracellular Domain of Death Receptor 5 Inhibits TRAIL-Induced Apoptosis by Disrupting Receptor-Receptor Interactions.
    Vunnam N; Lo CH; Grant BD; Thomas DD; Sachs JN
    J Mol Biol; 2017 Sep; 429(19):2943-2953. PubMed ID: 28834692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized.
    Valley CC; Lewis AK; Mudaliar DJ; Perlmutter JD; Braun AR; Karim CB; Thomas DD; Brody JR; Sachs JN
    J Biol Chem; 2012 Jun; 287(25):21265-78. PubMed ID: 22496450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
    Mérino D; Lalaoui N; Morizot A; Schneider P; Solary E; Micheau O
    Mol Cell Biol; 2006 Oct; 26(19):7046-55. PubMed ID: 16980609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
    Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
    Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.
    Guillaume YC; Lethier L; André C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1036-1037():142-148. PubMed ID: 27750195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha.
    Sheikh MS; Burns TF; Huang Y; Wu GS; Amundson S; Brooks KS; Fornace AJ; el-Deiry WS
    Cancer Res; 1998 Apr; 58(8):1593-8. PubMed ID: 9563466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs.
    Jayasooriya RG; Choi YH; Hyun JW; Kim GY
    Environ Toxicol Pharmacol; 2014 Nov; 38(3):959-67. PubMed ID: 25461556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
    Beyrath J; Chekkat N; Smulski CR; Lombardo CM; Lechner MC; Seguin C; Decossas M; Spanedda MV; Frisch B; Guichard G; Fournel S
    Oncotarget; 2016 Oct; 7(40):64942-64956. PubMed ID: 27409341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
    Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
    Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
    Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
    Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
    Oh YT; Deng J; Yue P; Owonikoko TK; Khuri FR; Sun SY
    Oncogene; 2016 Jan; 35(4):459-67. PubMed ID: 25867065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity.
    Uberti D; Ferrari-Toninelli G; Bonini SA; Sarnico I; Benarese M; Pizzi M; Benussi L; Ghidoni R; Binetti G; Spano P; Facchetti F; Memo M
    Neuropsychopharmacology; 2007 Apr; 32(4):872-80. PubMed ID: 16936710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells.
    Park KJ; Lee SH; Kim TI; Lee HW; Lee CH; Kim EH; Jang JY; Choi KS; Kwon MH; Kim YS
    Cancer Res; 2007 Aug; 67(15):7327-34. PubMed ID: 17671202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
    Neumann S; Hasenauer J; Pollak N; Scheurich P
    J Biol Chem; 2014 Jun; 289(23):16576-87. PubMed ID: 24764293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
    Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
    Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.
    Chang CC; Kuan CP; Lin JY; Lai JS; Ho TF
    Chem Res Toxicol; 2015 Aug; 28(8):1574-83. PubMed ID: 26203587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling and cell death in the immature central nervous system after hypoxia-ischemia and inflammation.
    Kichev A; Rousset CI; Baburamani AA; Levison SW; Wood TL; Gressens P; Thornton C; Hagberg H
    J Biol Chem; 2014 Mar; 289(13):9430-9. PubMed ID: 24509861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
    Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
    Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.